is microdosing legal?

not federally. lsd, psilocybin and psilocyn are schedule i substances under 21 cfr 1308.11(d), with no fda-approved product and no approved use. oregon and colorado permit supervised adult psilocybin sessions under state law, but not take-home microdose regimens, and federal law is unchanged. a product sold as a legal microdose either contains no psilocybin or lsd, in which case no trial has tested it, or it is not legal.

does microdosing help depression or anxiety?

the randomised evidence does not show it. the 2026 synthesis found no clear reduction in depressive symptoms (standardised mean difference -0.19, 95% ci -0.56 to 0.19), anxiety or stress, and a preregistered psilocybin crossover found no effect on anxiety, depression or emotion processing against placebo. no completed trial has tested microdosing in people diagnosed with depression. app surveys report lower depression scores in microdosers, but their authors say the design cannot show cause.

does microdosing help adhd or focus?

in the one trial in adults diagnosed with adhd, 20 micrograms of lsd twice a week for six weeks reduced symptoms by 7.1 points and placebo by 8.9, with no difference between them. two double-blind psilocybin truffle trials found no significant effect on cognitive control, memory or social cognition after correction, and a 34-person psilocybin trial found no gain in cognition, with a few small changes toward impairment.

in short trials of up to six weeks, microdoses were generally tolerated, with adverse events similar to placebo in the 2026 synthesis; anxiety made 4 of 40 men on lsd withdraw from one trial. what is not known is the effect of months of repeated dosing, including on heart valves, because lsd and psilocybin act on the 5-ht2b receptor linked to valve disease and no study has tested it. supply is unregulated, and tabs sold as lsd can contain more toxic nbome compounds. interactions with antidepressants at these doses have not been studied.

Substance evidence

Microdosing

Where placebo control is enforced, most of the benefit disappears.

page first published 2026-09-08 · last updated 2026-10-13

Not an FDA-approved treatmentSold outside the supplement category4 studies on this page

What Its Legal Status Actually Means

Read this before anything below it. Legal to sell is not the same fact as reviewed, verified, or approved.

The substances used for microdosing are federally illegal. Psilocybin, psilocyn, and lysergic acid diethylamide are all listed in Schedule I of the Controlled Substances Act at 21 CFR 1308.11(d) — the schedule reserved for drugs with no currently accepted medical use and a high potential for abuse — with no FDA-approved product and no approved indication of any kind. Nothing sold or shared as a "microdose" is an approved medicine; there is no legal, quality-controlled supply, so dose and purity are unverified. A small number of state and municipal programmes (for example Oregon's supervised psilocybin services and Colorado's healing centres) permit supervised adult use of psilocybin under state law, but those frameworks cover supervised sessions, not take-home microdose regimens, and they do not change federal law.

Quoted whole from the 2026-08-18 study harvest. Not summarized, not shortened.

does microdosing work? what the placebo-controlled trials and the law say

there is no fda label here: no microdose product, and no psilocybin or lsd product of any kind, is fda-approved. the legal facts are read from 21 cfr 1308.11(d), the federal schedule i list, as published on ecfr on 2026-10-13. the trial facts are from the study records on this page, each of which is a library row linked at the end, and from six further placebo-controlled trials and one safety review read from their pubmed abstracts on 2026-10-13, which are not yet library rows and are cited by doi. every source is linked at the end of this section. last checked 2026-10-13.

microdosing means taking a small fraction of a psychedelic dose, usually psilocybin mushrooms or lsd, every few days for weeks, with the aim of feeling better, focusing better or thinking more creatively without feeling high. the claims come mostly from surveys of people who chose to microdose, and those surveys report less depression, anxiety and stress. the trials that hid from people whether they were taking the drug or a placebo mostly found something different: people improved, but they improved about as much on placebo. this section says what the law says, what the placebo-controlled trials measured and in whom, what they found in both directions, why the surveys disagree, and what is and is not known about risk. every number is from a study record on this page, a trial abstract, or the federal schedule, and each source is linked at the end.

this is information to take to a prescriber or pharmacist. nothing here tells anyone to microdose or to stop, nothing here is a reason to stop or change a prescribed medication, and nothing here is a reason to put off treatment that works.

what the law says

lysergic acid diethylamide, psilocybin and psilocyn are each listed in schedule i of the federal controlled substances schedules, at 21 cfr 1308.11(d) [cfr]. schedule i is the list for drugs with no currently accepted medical use and a high potential for abuse, there is no fda-approved product containing any of them, and there is no approved indication of any kind [status]. a few states run supervised adult psilocybin programmes, oregon and colorado among them, but those cover supervised sessions, not take-home microdose regimens, and they do not change federal law [status].

two consequences follow for anyone reading about microdosing. first, there is no legal, quality-controlled supply, so the dose and purity of what people take is unverified: dried mushroom potency varies severalfold, and tabs sold as lsd are a common vehicle for nbome compounds, which are far more toxic [risks]. second, a product sold as a "legal microdose" is, by the schedule, either something other than psilocybin or lsd, in which case none of the trials below tested it, or it contains a schedule i substance and is not legal [cfr]. this page has found no trial of any product sold under that name.

what the placebo-controlled trials measured, in whom, and for how long

nine placebo-controlled trials, reported in eight papers, are cited here. lsd: 20 healthy young adults took single doses of 6.5, 13 and 26 micrograms or placebo a week apart [bershad-2019]; 56 healthy adults took four doses of 13 or 26 micrograms or placebo every three to four days in a laboratory [dewit-2022]; 80 healthy men took 14 doses of 10 micrograms or placebo every three days for six weeks, most of them at home [murphy-2023]; and 53 adults with a diagnosis of adhd and moderate to severe symptoms took 20 micrograms or placebo twice a week for six weeks, 12 doses in all [mueller-2025]. psilocybin: 34 people about to start microdosing took 0.5 g of dried mushroom or placebo under double-blind conditions [cavanna-2022]; a preregistered double-blind crossover study tested repeated psilocybin microdoses against placebo over three weeks, measuring mood and emotion processing after the seventh dose [marschall-2022]; and two further double-blind trials of psilocybin truffles measured cognition, memory, social cognition and wellbeing [prochazkova-2026]. the largest placebo design is not a laboratory trial: 191 people already planning to microdose followed online instructions to build their own placebo control into their routine, so that they did not know on a given day whether they had taken a microdose or an empty capsule, for four weeks [szigeti-2021].

three facts travel with that list. only one of the trials, the adhd trial, was in people with a diagnosed condition; the rest were in healthy or self-selected volunteers, and the harvest records that no microdosing trial in a diagnosed psychiatric population met its inclusion rules as of august 2026 [mueller-2025; exclusions]. none ran longer than six weeks [murphy-2023; mueller-2025]. and blinding is fragile: in the psilocybin crossover, participants broke blind in the second block [marschall-2022], and in the 34-person trial the stronger subjective effects appeared only in people who correctly guessed they had the active dose [cavanna-2022]. a 2021 review argues that most psychedelic trials have not measured pre-trial expectation or whether blinding held, and that their effect sizes are likely overestimated as a result [muthukumaraswamy-2021].

what the research says, in both directions

in favour. the surveys are consistent and large. among 4,050 microdosers and 4,653 non-microdosers recruited through a phone app, microdosers who reported mental health concerns had lower depression, anxiety and stress scores [rootman-2021]. in the prospective version, 953 psilocybin microdosers followed for about 30 days showed small to medium improvements in mood and mental health against 180 non-microdosers, and in people with mental health concerns average depression scores moved from moderate to mild [rootman-2022]. in a six-week diary study of 98 microdosers, psychological functioning rose on dosing days, and depression and stress were lower at the end [polito-2019]. the drug does do something at these doses: lsd produced dose-related subjective effects from 6.5 micrograms up, and increased vigor at 26 micrograms [bershad-2019]; in the 80-man home trial, ratings of creativity, connectedness, energy, happiness, wellness and irritability were credibly better on dose days than on non-dose days, and that held after controlling for expectation [murphy-2023].

against, or smaller than it sounds. in the 191-person self-blinding study every psychological outcome improved over four weeks in the microdose group, and improved just as much on placebo [szigeti-2021]. in the adhd trial, symptom scores fell by 7.1 points on lsd and by 8.9 points on placebo, with no difference between the groups [mueller-2025]. in the 80-man trial, no questionnaire or cognitive task changed between the start and the six-week end, so the dose-day lift did not add up to lasting change [murphy-2023]. repeated 13 and 26 microgram doses "did not improve mood or affect performance" [dewit-2022]. psilocybin did not affect emotion processing or anxiety and depression against placebo in the preregistered crossover [marschall-2022], did not significantly affect any behavioural or subjective measure after correction for multiple comparisons in the two truffle trials [prochazkova-2026], and in the 34-person trial showed no benefit on wellbeing, creativity, cognition or perception, with a few small changes toward cognitive impairment [cavanna-2022]. the most recent synthesis, 24 studies and 3,681 people searched to february 2026, found no clear reduction in depressive symptoms (standardised mean difference -0.19, 95% ci -0.56 to 0.19), anxiety or stress in randomised trials, and attributed the survey improvements to expectancy and lifestyle [meshkat-2026]. that synthesis rests on very little randomised data, so it shows an absence of evidence more than proof of no effect [meshkat-2026].

why the two sides disagree. the surveys recruited people who chose to microdose, through venues favourable to psychedelic use, which their authors name as a source of bias [rootman-2021; rootman-2022]; the cross-sectional one says its design "precludes causal inference" [rootman-2021]. a companion survey of 263 people found that expectations of benefit were large and largely unrelated to what microdosers actually reported, which is the signature of expectation rather than pharmacology; the same diary study found neuroticism went up [polito-2019]. the app studies were run on a platform owned by some of their authors, and one author holds pending patents on a psilocybin combination, all declared in the papers [rootman-2021; rootman-2022]. the null trials do not come from sceptics either: the 2026 synthesis has authors at psychedelic research centres [meshkat-2026], and the adhd trial was funded in part by a psychedelic drug developer [mueller-2025].

the risks, measured and unmeasured

measured. in the trials, microdoses were generally tolerated: the adhd trial called lsd "physically safe and psychologically well tolerated overall" [mueller-2025], and the 2026 synthesis found adverse-event rates similar to control [meshkat-2026]. the most notable adverse event in the 80-man trial was anxiety, which made 4 of the 40 men on lsd withdraw [murphy-2023]. negative bodily feelings were stronger on active psilocybin than on placebo in the truffle trials [prochazkova-2026].

unmeasured. microdosing means repeated dosing over weeks or months, and no trial has run long enough to describe chronic effects [risks]. the concern most discussed is the heart: lsd and psilocybin’s active form bind the serotonin 5-ht2b receptor, the receptor implicated in the valve disease caused by fenfluramine and pergolide. a 2023 review of every in vitro, animal and clinical study found the compounds are partial agonists at that receptor, that safety margins at typical microdoses were wider than for the known valve-damaging drugs "but not without potential risk", and that no animal or clinical study designed to test valve risk exists for any psychedelic [tagen-2023]. all but one of its authors list private companies as their affiliation (verdient science and delos therapeutics), not universities [tagen-2023]. that is an unquantified risk, not a demonstrated one. people with a personal or family history of psychosis or bipolar disorder are excluded from psychedelic trials, and interactions with antidepressants have not been characterised at these doses [risks]. the only interaction evidence in this library is a retrospective survey in which people taking psilocybin mushrooms with an ssri or snri often reported weaker effects than expected; it is about full doses and says nothing about safety at microdoses [gukasyan-2023].

questions for a prescriber or pharmacist about microdosing

each one comes from a warning or a study above. they are questions, not instructions; the answers depend on a history nobody here has.

in the placebo-controlled trials, people on placebo improved about as much as people on a microdose. how would we tell whether what i feel is the substance or the expectation?
the only trial in a diagnosed condition, adult adhd, found no difference from placebo. is there a treatment for what i have with an effect shown against placebo that we have not tried?
i take an antidepressant, lithium or another psychiatric drug. interactions at microdoses have not been studied. what would you want to know before i took anything else?
is there psychosis or bipolar disorder in my family, and does that change anything?
no study has tested whether months of microdosing affects heart valves. is there anything in my heart history that matters here?
what i would take comes from an unregulated source, and tabs sold as lsd can contain nbome compounds. what are the signs that something is wrong after taking it?

questions people ask

does microdosing work?: not better than placebo in the trials that hid which was which. in the largest placebo design, 191 people improved as much on empty capsules as on microdoses over four weeks. in 53 adults with adhd, symptoms fell by 7.1 points on lsd and 8.9 on placebo. in 80 healthy men, mood and energy were better on dose days, but nothing had changed after six weeks. a 2026 synthesis of 24 studies found no clear effect on depression, anxiety or stress in randomised trials. surveys of people who chose to microdose report benefits, but they cannot separate the drug from expectation.
is microdosing legal?: not federally. lsd, psilocybin and psilocyn are schedule i substances under 21 cfr 1308.11(d), with no fda-approved product and no approved use. oregon and colorado permit supervised adult psilocybin sessions under state law, but not take-home microdose regimens, and federal law is unchanged. a product sold as a legal microdose either contains no psilocybin or lsd, in which case no trial has tested it, or it is not legal.
does microdosing help depression or anxiety?: the randomised evidence does not show it. the 2026 synthesis found no clear reduction in depressive symptoms (standardised mean difference -0.19, 95% ci -0.56 to 0.19), anxiety or stress, and a preregistered psilocybin crossover found no effect on anxiety, depression or emotion processing against placebo. no completed trial has tested microdosing in people diagnosed with depression. app surveys report lower depression scores in microdosers, but their authors say the design cannot show cause.
does microdosing help adhd or focus?: in the one trial in adults diagnosed with adhd, 20 micrograms of lsd twice a week for six weeks reduced symptoms by 7.1 points and placebo by 8.9, with no difference between them. two double-blind psilocybin truffle trials found no significant effect on cognitive control, memory or social cognition after correction, and a 34-person psilocybin trial found no gain in cognition, with a few small changes toward impairment.
is microdosing safe?: in short trials of up to six weeks, microdoses were generally tolerated, with adverse events similar to placebo in the 2026 synthesis; anxiety made 4 of 40 men on lsd withdraw from one trial. what is not known is the effect of months of repeated dosing, including on heart valves, because lsd and psilocybin act on the 5-ht2b receptor linked to valve disease and no study has tested it. supply is unregulated, and tabs sold as lsd can contain more toxic nbome compounds. interactions with antidepressants at these doses have not been studied.

sources for this section

the library rows link to our one-page summary of each study, with the original paper, its funding and our evidence grade on that page.

What the Research Shows

4 records from the 2026-08-18 harvest, each checked against PubMed and Europe PMC on that date. How a study was designed, how many people were in it, and who paid for it are printed above what it found, because those three facts decide how much the finding is worth.

Study 1 · 2026
- Systematic review of randomized trials
- 3,681 participants
- Reputable journal
- Funding not established
- Preregistered
- Declared conflicts of interest
strong72/100
Well-supported by good-quality research.
Read this first: The meta-analytic estimates rest on very little randomised data — two parallel RCTs (three comparisons, n=117) for efficacy and two RCTs (n=109) for adverse events — so the confidence intervals are wide and the review is better read as demonstrating absence of evidence than proving absence of effect. Several authors are affiliated with psychedelic research centres and one is chief medical officer of a psychedelics company (disclosed), so the null result is not coming from sceptics.
The most recent synthesis — 24 studies and 3,681 participants, searched to February 2026 — found that in randomised trials microdosing produced no clear reduction in depressive symptoms (SMD -0.19, 95% CI -0.56 to 0.19), anxiety (SMD -0.20, -1.11 to 0.71), or stress (SMD 0.02, -0.39 to 0.43), with adverse-event rates similar to control. Observational studies reported mood and personality improvements, which the authors attribute to expectancy and lifestyle factors rather than drug effect.
Meshkat S, Leung M, Meshkat S, et al. (2026). Efficacy and Safety of Psychedelic Microdosing on Psychological Outcomes in Healthy Adults: A Systematic Review and Meta-analysis. CNS Drugs. PMID 42593636.
How this record was checked
PubMed record 42593636 fetched via NCBI efetch 2026-08-18; title, authors, journal, publication (CNS Drugs, online ahead of print 13 Aug 2026), DOI, 24 studies, 3,681 participants, PROSPERO registration CRD420251035294, all three SMDs, and the conflict-of-interest declaration confirmed from the record. Europe PMC core record checked the same day: not open access, no grant or funding statement retrievable and the publisher page is behind authentication, so funding is recorded UNKNOWN.
Study 2 · 2021
- Randomized trial
- 191 participants
- Reputable journal
- No funding reported
- Declared conflicts of interest
strong70/100
Well-supported by good-quality research.
Read this first: Participants sourced and weighed their own material, so actual doses were unverified, and the sample was self-selected enthusiasts rather than people with a diagnosed condition. The authors are based at Imperial College's Centre for Psychedelic Research with a co-author from the Beckley Foundation, both proponents of psychedelic research — which cuts against, not toward, a bias explanation for this null result.
191 people already intending to microdose followed online instructions to build their own placebo control into their routine. Every psychological outcome improved from baseline over four weeks in the microdose group — and improved just as much in the placebo group, with no significant between-group differences. The few acute differences that did appear were explained by participants correctly guessing which capsules were active.
Szigeti B, Kartner L, Blemings A, et al. (2021). Self-blinding citizen science to explore psychedelic microdosing. eLife. PMID 33648632.
How this record was checked
PubMed record 33648632 fetched via NCBI efetch 2026-08-18; title, authors, journal, year, DOI, and n=191 completers confirmed from the abstract, along with the competing interests declaration ("no competing interests declared"). Europe PMC full text (PMC7925122) fetched the same day states "No external funding was received for this work", hence funding NONE; no preregistration statement found in the full text, so preregistered is recorded false.
Study 3 · 2022
- Randomized trial
- 34 participants
- Reputable journal
- Independently funded
- Declared conflicts of interest
strong78/100
Well-supported by good-quality research.
Read this first: With 34 participants the study is underpowered to detect small true effects, and the authors' own Bayesian analysis in the successfully blinded subgroup was inconclusive rather than clearly negative.
34 people beginning to microdose took 0.5 g of dried Psilocybe cubensis or placebo under double-blind conditions. Subjective effects were stronger on the active dose only among participants who correctly guessed which condition they were in, and EEG theta power dropped; on every other measure — wellbeing, creativity, cognition, perception — there was no benefit, with a few small changes in the direction of cognitive impairment.
Cavanna F, Muller S, de la Fuente LA, et al. (2022). Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. Translational Psychiatry. PMID 35918311.
How this record was checked
PubMed record 35918311 fetched via NCBI efetch 2026-08-18; title, authors, journal, year, DOI, n=34, and the 0.5 g dose confirmed from the abstract, along with the competing-interests declaration. Europe PMC full text (PMC9346139) fetched the same day: funded by grant PICT-2019-02294 from Argentina's Agencia Nacional de Promoción Científica y Tecnológica with partial funding from the Czech Ministry of Health (NU21-04-00307) and the Czech Science Foundation (20-25349S) — all public agencies, hence INDEPENDENT.
Study 4 · 2019
- Cohort study
- 98 participants
- Indexed journal
- No funding reported
- Declared conflicts of interest
moderate64/100
Reasonable evidence with real limitations.
Read this first: Uncontrolled and unblinded: participants knew they were dosing, sourced their own substances, and were self-selected enthusiasts, so nothing here can separate drug effect from expectation. The authors say as much and explicitly call for dose- controlled research.
98 microdosers gave daily ratings over six weeks: psychological functioning rose on dosing days with little carry-over to the following days, and pre-to-post measures showed lower depression and stress and less distractibility — but also higher neuroticism. A companion survey of 263 people found that expectations of benefit were large, wide-ranging, and largely unrelated to what the actual microdosers reported, which is the signature of expectancy rather than pharmacology.
Polito V, Stevenson RJ. (2019). A systematic study of microdosing psychedelics. PLOS ONE. PMID 30726251.
How this record was checked
PubMed record 30726251 fetched via NCBI efetch 2026-08-18; title, authors, journal, year, DOI, and the sample sizes (98 daily-rating participants, 63 completing psychometrics, 263 in the expectancy study) confirmed from the abstract. Europe PMC full text (PMC6364961) fetched the same day states "The authors received no specific funding for this work", hence funding NONE, and declares no competing interests.

The Risks

Nobody checks this purchase the way a prescription is checked. No prescriber reviews it against the rest of what you take, no pharmacist screens the interaction, and no regulator confirms the dose in the capsule before it is sold. That is why this section sits here at full length rather than as a footnote.

What the paragraph below covers:

Heart and blood pressure
Psychosis and mania
Drug interactions
What is actually in the product

Possession is a federal felony and material is bought from unregulated sources, so the identity, purity, and strength of what people take is unknown — dried mushroom potency varies severalfold and "LSD" tabs are a common vehicle for substituted NBOMe compounds, which are far more toxic. Because microdosing means repeated dosing over weeks or months, its risk profile is not the same as a single supervised session: no trial has run long enough to characterise chronic effects. The most-discussed theoretical concern is cardiac — psilocin and LSD are agonists at the 5-HT2B receptor, the same receptor implicated in the valvular heart disease caused by fenfluramine and pergolide, and sustained low-level 5-HT2B agonism is the exposure pattern that caused that damage; no study has yet tested whether chronic microdosing does the same, so this is an unquantified risk rather than a demonstrated one. Controlled studies have found small shifts toward cognitive impairment rather than enhancement, and self-report studies list physiological discomfort and increased anxiety among reported downsides. People with a personal or family history of psychosis or bipolar disorder are excluded from psychedelic trials for good reason, and serotonergic interactions with antidepressants are not characterised at these doses.

What Is Not Known

The boundaries of the section above, in the harvest’s own words. What it excluded, why, and where it looked and found nothing. An absence of evidence is not evidence of absence, and it is not evidence of benefit either.

This file is the honest counterweight to the clinical psychedelics lane. Macro-dose psilocybin and MDMA trials — supervised, single or double sessions, with psychological support — live in the 2026-08-17 PSYCHEDELICS batch and are a different intervention with a different evidence base. Microdosing means sub-perceptual doses (roughly a tenth of a recreational dose) taken repeatedly, usually unsupervised and self-sourced. The controlled evidence for it points the other way: where placebo control is enforced, the benefits largely disappear.

What Was Left Out, and Why

Quoted from the harvest, where these notes sat above the study list rather than after it. Where a note says “below” it means the studies in the section above.

Open-label and uncontrolled microdosing surveys (Anderson 2019, Rootman 2021 and similar app-based cohorts) excluded: every one of them is self-selected, and the controlled studies below exist precisely to test what those surveys cannot.
Lo 2024 systematic review in Prim Care Companion CNS Disord (PMID 38228068) was verified but dropped in favour of the 2026 CNS Drugs meta-analysis, which supersedes it and actually pools effect sizes.
No microdosing study in a clinical population with a diagnosed psychiatric disorder met inclusion; all controlled work below is in healthy or self-selected volunteers. That absence is itself the finding.

The Retraction Check

PubMed efetch records for all four PMIDs (33648632, 35918311, 30726251, 42593636) inspected 2026-08-18 for "Retraction in" flags; none present.

Questions for a Prescriber or Pharmacist

This page does not tell anyone to take Microdosing or to avoid it. It is not able to: it does not know what else you take, what you have tried, or what you are treating. These are the questions each study above raises, written to be asked out loud.

The randomised evidence shows microdosing performing no better than placebo for depression, anxiety, or stress — what treatment with an actual demonstrated effect should I be trying first?
In the largest placebo-controlled microdosing study, people taking empty capsules improved as much as people taking the drug — how do I tell whether what I am feeling is the substance or the expectation?
This study found the only reliable difference from placebo was in people who knew they had taken the active dose, and no gain in creativity or cognition — what am I actually expecting microdosing to do for me?
Observational microdosing data show people expect far more benefit than users actually report, and one measure — neuroticism — went up. Is that a trade I would knowingly make?

And the one to ask at the counter, whatever the answers above turn out to be: given everything I am already taking, what would you want to know about Microdosing before I put it in the same body?

Open Microdosing in veisund

The app has the resources behind this page and people working through the same questions.What you post there goes to people, not to a model. If someone answers, it is a person who has been there. The one automated message is a crisis-resource reply.

Where This Page Comes From

Transcribed from the study-harvest-2026-08-18 record for microdosing, built into this page by scripts/supplement-ingest.mjs on 2026-09-07. Nothing here is fetched at page load, and nothing here was written by a model without a citation behind it.

Source file	study-harvest/2026-08-18/microdosing.yaml
Source repo	REPTechnologies/avalo-backend
SHA-256	2170832b91cbb71ac8031c350f639b781d2f3252c399eb0f8a11d10274422143
Also searched as	microdose, LSD microdosing, psilocybin microdosing, sub-perceptual dosing

The Other Substances

Do any supplements actually work? asks the question across all of them. The full library has the medication records, the funding investigations, and the glossary.